



Non-alcoholic Fatty Liver Disease and Cholesterol: The Lesser-known Links

**Anshool Kumbhare ^a, Sanket Bakshi ^a, Aman Agrawal ^a
and Anand Bakre ^{b*}**

^a *Jawaharlal Nehru Medical College, Datta Meghe institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha – 442001, Maharashtra, India.*

^b *Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha – 442001, Maharashtra, India.*

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i60B34726

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: <https://www.sdiarticle5.com/review-history/79781>

Review Article

Received 15 October 2021
Accepted 20 December 2021
Published 23 December 2021

ABSTRACT

Non Alcoholic Fatty Liver Disease refers to a group of hepatic histological abnormalities that ranges from noninflammatory intra-cellular lipid collection to NASH develop, fibrosis, or hepato-cellular carcinoma, which results from a mismatch between lipid supply and lipid clearance, is a characteristic of Non Alcoholic Fatty Liver Disease. Recent buildup aetiology. Hepatic FC build up in Non Alcoholic Fatty Liver Disease is caused by changes in intracellular cholesterol transport as well as a poorly balanced cellular cholesterol equilibrium characterized by an increased, and amplification of routes. With the induction of intra-cellular signalling pathway in stellate cells, Kupffer cells, including hepatocyte, FC build up causes liver damage. Inflammation and fibrogenesis are aided by the activation of Kupffer cells and stellate cells.. These episodes feed a never-ending cycle, which helps in forming steatosis while also promoting liver cells mortality, and hepatic injury, that can lead to disease progression. In this review, we highlight what we know about NAFLD's dysfunctional cholesterol homeostasis and look at the liver pathophysiology and how they contribute to the disease's continuous liver injury. This knowledge's treatment implications are also highlighted. Inflammation and fibrogenesis are aided by the activation of KCs and HSCs.

[≡] MBBS Student;

[°] Associate professor;

*Corresponding author: E-mail: dranandbakre@gmail.com;

Furthermore, FC buildup in liver mitochondria causes mitochondrial malfunction, which leads to an increase in reactive oxygen species generation, as well as the unsettled response of proteins in the ER (endoplasmic reticulum), which leads to endoplasmic reticulum death.

Keywords: NPC1L1; ezetimibe; statins; bile acids; fatty liver; Choles.

1. INTRODUCTION

Insulin resistance, overweight, atherogenic dyslipidemia, and hypertension are all established cardiovascular risk factors that occur together in the metabolic syndrome [1]. Lipid build-up in the hepatic that is unrelated to liquor in hepatocytes is the important feature. Because of dyslipidaemia and insulin resistance, lipids accumulate in hepatocytes, causing hepatic injury and triggering a complex reaction those results in liver fibrosis and inflammation. There is unmistakable proof that cardiovascular disease is the biggest cause of mortality in NAFLD patients [2]. Enhanced fatty acid flow, which is linked to resistance of insulin or/and raised lipogenesis de novo in the hepatic cells, is thought in causing fatty-acid buildup in the hepatocyte and lip toxicity. NAFLD is defined by the accumulation of triglycerides and free cholesterol (FC) without a commensurate increase in cholesterol esters [3]. However, new research suggests that an elevated amount of cellular cholesterol has the formation of NAFLD and the disease's progression. We will offer a brief overview of the processes involved in maintaining address in this review. In NAFLD patients, cardiovascular disease is the primary cause of death. As a result, implementing an aggressive dyslipidaemia treatment plan with hypolipidemic drugs may reduce the risk of CVD in NAFLD patients [4]. There is also a summary of current understanding about the medicines therapy people.

2. METHODS

2.1 Protocol and Registration

The review protocol was registered at Jawaharlal Nehru Medical College. The review was limited to the role of cholesterol in NAFLD.

2.2 Search Strategy

We used Medline, EMBASE, and the Cochrane Library to conduct our research. NAFLD OR NASH OR non-alcoholic hepatitis OR liver fat OR fatty liver OR liver enzyme OR Alanine

transaminase OR ALT OR GGT OR AST OR increased severity of liver disease were used as search terms. Only English-language publications were found in the search results. Additional relevant research were found by individually searching the sources of the included publications.

2.3 Study Selection

In this literature review, we included certain observational studies, case report, reviews and various original scientific research papers. We included studies which depicted a co relation between NAFLD and various biochemical serum markers. Only the most recent articles were considered for this review.

3. RESULTS

3.1 The Studies' Characteristics

The first research review yielded 460 papers, 21 of which were potentially appropriate for the viewing, but only Nine research, 6 of which involved adult's and three of which involved children and teenagers, could be included in the final assessment. The methodological quality of the studies chosen was excellent in general.

3.1.1 Adult studies

The investigations involved 629 elderly people suffering from Non Alcoholic Fatty Liver Disease and 1237 healthy control. In certain research, control participants are matched for age and gender, whereas in another, they are compelled for age, gender, and BMI - body mass index and waist circumference. Five of the investigations were case control studies in hospitals, while one was a population-based cross-sectional survey. NAFLD was defined in one study by liver histology, four studies by ultrasonography, and one study by computed tomography scan. When fatty acid intake and de novo lipogenesis overwhelm lipid acid oxidation and export, liver steatosis develops [5]. Three trials included just nondiabetic, normotensive people, one included type 2 diabetic patients, and one included people

with never-treated waist circumference. Lipid buildup in hepatocytes damages the liver and leads to inflammation, fibrosis, and cirrhosis [6]. Five of the investigations were case-control studies in hospitals, while one was a population-based cross-sectional survey. Compared to occurrence statistics, there are far more articles reporting the prevalence of NAFLD in the public. A new meta-analysis of the epidemiology of NAFLD [7] summarises these research.

We look at the consequences of increased FC in hepatocyte, HSCs - liver stellate cell, KC Cells - Kupffer cells, as well as subcellular process in the way in which increased FC can cause cellular toxicities, pro-inflammatory, and pro-fibrotic impact in the cells, in this review. Was in one study histology, four studies by ultrasonography, and one study by computed tomography scan. Non Alcoholic Fatty Liver Disease is a group of hepatic disorders that range from NAFL - non-alcoholic fatty liver to NASH non-alcoholic steatohepatitis that can develop to cirrhosis and liver cancer [8]. Three studies included only nondiabetic, normotensive people, one included type 2 diabetic patients, and one included patients who had never been treated for essential hypertension. Patients with NAFLD and MetS were included in the population-based study.

3.1.2 Paediatric studies

The consequences of NAFLD on cardiac anatomy and function in children and adolescents have been studied extensively. The investigations included 243 obese children suffering from Non Alcoholic Fatty Liver Disease, 681 obese subjects without liver involvement, and 236 healthy controls who were age and gender matched. Evidence accumulating over the last few decades strongly [9]. NAFLD was characterised in one study by ultrasound, in another study by ultrasound and increased serum ALT, and in yet another study by MRI (with liver biopsy in a subgroup).

NAFLD, as the name indicates, is characterised as accumulation of fats in the hepatic cells. The accumulation of triglycerides and free fatty-acid is a defining trait, which has also been linked to insulin resistance and obesity, at least in part. arginosuccinate major synthesis [10], where created situations. As a result, the pathogenic components of NAFLD are complicated and multifaceted, with various explanations being proposed in the literature. The first hit of Non

Alcoholic Fatty Liver Disease generation has been hypothesised, with lipid build up in liver, lazy lifestyle, increased intake of fatty foods, overweight, and resistance to insulin as the first hit. The second blow triggers an inflammatory response that leads to fibrogenesis. In type 2 diabetes patients, L-arginine therapy improves but does not entirely normalise peripheral and hepatic insulin sensitivity [11]. This two-hit model has fallen out of favour because it was deemed too basic to fully portray the intricacies of individual NAFLD/e, which involves a number of variables interacting in a biologically susceptible person. A multitude of factors play a role in the development of NAFLD, as indicated in the predisposing factors section. A multitude of factors play a part in the establishment of Non Alcoholic Fatty Liver Disease, as indicated in the predisposing factors section. Insulin resistance, on the other hand, is a key element in the progression of NASH because it induces liver de novo lipogenesis and a decrease in adipose tissue lipolysis, leading to a rise in fatty- acids in the hepatic. Adipokine and inflammatory cytokine synthesis and secretion changes as a result of adipose tissue malfunction caused by insulin resistance as mentioned in the risk factors section, a variety of factors have a role in the establishment of NAFLD. Insulin resistance, on the other hand, is a crucial factor in the establishment of NASH, since it causes liver lipogenesis de novo and a decrease in lipolysis of adipose tissue, resulting in an increment in fatty acids in the hepatic [12]. Adipokine and inflammatory cytokine synthesis and secretion changes because of adipose tissue malfunction caused by insulin resistance. As a result, the use of particular probiotics to alter intestinal bacterial flora has also been advocated in the treatment method for management of NASH. Overweight, Type 2 diabetes mellitus, and Non Alcoholic Fatty Liver Disease all have defective fatty tissue, which impacts lipid and glucose metabolism through two routes: First, by trying to act as endocrine gland, going to release an amount of fat-derived cytokines; and second, by ectopic fat deposition and lip toxicity induced by free fatty acids. NAFLD (non-alcoholic fatty liver disease) is a chronic hepatic condition linked to overweight and metabolic syndrome. Hepatic histologically, encompassing basic eventual. Insulin resistance, overweight, atherogenic dyslipidemia, and hypertension are all established cardiovascular risk factors that occur together in the metabolic syndrome. Lipid buildup in the hepatic that is unrelated to liquor in hepatocytes is the important feature. As a

consequence of dyslipidaemia and insulin resistance, lipids accumulate in hepatocytes, causing hepatic injury and triggering a complex reaction that results in liver fibrosis and inflammation. There is unmistakable proof that cardiovascular disease is the biggest cause of mortality in NAFLD patients. Enhanced fatty acid flow, which is linked to resistance of insulin or/and raised lipogenesis de novo in the hepatic cells, is thought in causing fatty-acid buildup in the hepatocyte and lip toxicity. NAFLD is defined by the accumulation of triglycerides and free cholesterol (FC) without a commensurate increase in cholesterol esters. However, new research suggests that an elevated amount of cellular cholesterol has formation and diseases. Function crucial because it could lead to the discovery of new molecular mechanisms for effective NAFLD therapies. We will offer a brief overview of the processes involved in maintaining address in this review. In NAFLD patients, cardiovascular disease is the primary cause of death. As a result, implementing an aggressive dyslipidaemia treatment plan with hypolipidemic drugs may reduce the risk of CVD in NAFLD patients.

Raised triglycerides and r, which causes NAFLD to spread not only in the United States but also around the world. In most cases, liver steatosis is harmless, but in the establishment and progression of fibrosis is not, and it signals a weak prognosis. Many prognostic factors generation Disease has proposed, with the majority of them including some metabolic abnormality or insulin resistance as the pathogenesis. Furthermore, increased access and lower costs for increased quality, High powered genetic analysis will undoubtedly present further doctors with a wealth of knowledge and opportunities for more tailored treatment. The development of sophisticated imaging and biochemical tests is in the same boat. Several supplements are already available; by way, none appear as a "magic bullet" for addressing this expanding disease. The importance of a healthy lifestyle, together with a balanced diet and regular exercise, in preventing NAFLD cannot be overstated.

The liver is an important organ in cholesterol metabolism regulation. Different surface proteins, and also as the LDLR - low-density lipoprotein receptor and the scavenger receptor class B type I, are involved in the uptake of cholesterol from lipoproteins (SR-BI).

4. DISCUSSION

By lowering FAS gene expression and protein levels, BCAA can help to reduce hepatic steatosis and liver damage associated with NASH [13]. Fat accumulation is a notably severe. According to research that is more recent. . Non-alcoholic fatty liver disease (NAFLD) is a growing body of research, with a high prevalence and the tendency to develop to its inflammatory counterpart (non-alcoholic steatohepatitis, or NASH) [14]. Additionally, epidemiological studies linking dietary cholesterol intake to the likelihood and severity of NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a rapidly emerging disorder with an increased proportion and the potential to evolve into its inflamed analog (non-alcoholic steatohepatitis, or NASH) [14] T2D subjects with NAFLD as indicated by reductions in liver fat in NASH, T2D individuals with NAFLD [15-18,19-21]. Furthermore, the lipid-lowering drug ezetimibe's potentially positive effects.

Furthermore, multiple research has discovered that HMGCR expression or function are elevated in the liver tissue of Non Alcoholic Fatty Liver Disease individuals, which is linked to a reduction in HMGCR phosphorylation with elevated enzymatic activities. Furthermore, because elevated liver FC concentrations and LDLR expression were linked to SREBP-2 upregulation in NASH individuals, elevated liver amounts of activated SREBP2, the major molecule that regulates cholesterol production, could be a factor.

5. CONCLUSIONS

NAFLD - Non Alcoholic Fatty Liver Disease refers to a group of hepatic histological abnormalities that ranges from noninflammatory intra-cellular lipid collection to NASH develop, fibrosis, or hepato-cellular carcinoma, which results from a mismatch between lipid supply and lipid clearance, is a characteristic of NAFLD. Recent buildup aetiology. Hepatic FC buildup in NAFLD is caused by changes in intracellular cholesterol transport as well as a poorly balanced cellular cholesterol equilibrium characterized by an increased, and amplification of routes. With the induction of intra-cellular signalling pathway in stellate cells (HSCs), Kupffer cells (KCs), including hepatocyte, FC buildup causes liver damage. Inflammation and fibrogenesis are aided by the activation of KCs and HSCs. Furthermore, FC buildup in liver mitochondria causes mitochondrial malfunction,

which leads to an increase in reactive oxygen species generation, as well as the unsettled response of proteins in the ER (endoplasmic reticulum), which leads to Endoplasmic Reticulum stress and death. These episodes feed a never-ending cycle, which helps in forming steatosis while also promoting liver cells mortality, and hepatic injury, that can lead to disease progression. In this review, we highlight what we know about NAFLD's dysfunctional cholesterol homeostasis and look at the liver pathophysiologies and how they contribute to the disease's continuous liver injury. This knowledge's treatment implications are also highlighted. Inflammation and fibrogenesis are aided by the activation of KCs and HSCs. Furthermore, FC buildup in liver mitochondria causes mitochondrial malfunction, which leads to an increase in reactive oxygen species generation, as well as the unsettled response of proteins in the ER (endoplasmic reticulum), which leads to Endoplasmic Reticulum death. Increased amount of FC in liver cells and non-parenchymal liver cells could be credited to dietary sources as well as a broad range of modifications in liver cholesterol Equilibrium. Raised FC in subcellular compartments like the Endoplasmic Reticulum and mitochondria in hepatocytes may trigger Endoplasmic Reticulum stress and mitochondrial impairment. As a consequence, liver cholesterol development rather than triglyceride accumulation is linked to continued hepatocyte death and liver damage, and may play a role in the evolution of NAFLD illness from simple steatosis to steatohepatitis. NAFLD - Non Alcoholic Fatty Liver Disease refers to a group of hepatic histological abnormalities that ranges from noninflammatory intra-cellular lipid collection to NASH, develop, fibrosis, or hepato-cellular carcinoma, which results from a mismatch between lipid supply and lipid clearance, is a characteristic of NAFLD. Recent evidence suggests that hepatic cholesterol homeostasis and liver free cholesterol (FC) buildup play a role in hepatic aetiology. Hepatic FC buildup in NAFLD is caused by changes in intracellular cholesterol transport as well as a poorly balanced cellular cholesterol equilibrium characterized by an increased lipid de-esterification, and amplification of cholesterol export and bile acid synthesis routes. With the induction of intra-cellular signalling pathway in stellate cells (HSCs), Kupffer cells (KCs), including hepatocyte, FC buildup causes liver damage. Inflammation and fibrogenesis are aided by the activation of KCs and HSCs. Furthermore, FC buildup in liver

mitochondria causes mitochondrial malfunction, which leads to an increase in reactive oxygen species generation, as well as the unsettled response of proteins in the ER (endoplasmic reticulum), which leads to Endoplasmic Reticulum stress and death. These episodes feed a never-ending cycle, which helps in forming steatosis while also promoting liver cells mortality, and hepatic injury, that can lead to disease progression. In this review, we highlight what we know about NAFLD's dysfunctional cholesterol homeostasis and look at the liver pathophysiologies and how they contribute to the disease's continuous liver injury. This knowledge's treatment implications are also highlighted. Inflammation and fibrogenesis are aided by the activation of KCs and HSCs. Furthermore, FC buildup in liver mitochondria causes mitochondrial malfunction, which leads to an increase in reactive oxygen species generation, as well as the unsettled response of proteins in the ER (endoplasmic reticulum), which leads to Endoplasmic Reticulum stress and death.

As a result, targeting cholesterol deposition as a treatment approach for NAFLD could be helpful. In the clinical scenario, would very certainly. Drugs recently used to manage dyslipidemia are beneficial in NASH/NAFLD, but this impact has to be studied in major clinical trials. Moreover, new methods that target sufferers.

Medical literature tells that liver fat metabolism. Inflammation and fibrogenesis were facilitated by the FC accumulating in liver mitochondria creates mitochondrial malfunction, which leads to increase in reactive oxygen species emission. Viscous leads to accumulation of while also boosting mortality and liver injury, which can result to disease development. In this review, we review what we know regarding NAFLD's dysregulated cholesterol homeostasis and look at the cellular mechanisms of hepatic FC toxicity as well as how they underlie to the disease's continuous liver injury. The therapeutic implementation of this knowledge are also discussed.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for

any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Huang PL. A comprehensive definition for metabolic syndrome. *Dis Model Mech.* 2009;2:231–7. DOI: 10.1242/dmm.001180
2. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with non-alcoholic fatty liver disease. *Semin Liver Dis.* 2012;32:22–9. DOI: 10.1055/s-0032-1306423
3. Kerr TA, Davidson NO. Cholesterol and NAFLD: renewed focus on an old villain. *Hepatology.* 2012;56:1995–8. DOI: 10.1002/hep.26088
4. Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. *J Clin Transl Hepatol.* 2015;3:78–84. DOI: 10.14218/JCTH.2014.00037
5. Ipsen DH, Lykkesfeldt J, Tveden-Nyborg P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cell Mol Life Sci.* 2018;75:3313–27. DOI: 10.1007/s00018-018-2860-6
6. Ioannou GN. The role of cholesterol in the pathogenesis of NASH. *Trends Endocrinol Metab.* 2016;27:84–95. DOI: 10.1016/j.tem.2015.11.008
7. Chalasani N. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology.* 2012; 142:1592-1609.
8. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nat. Med.* 2018;24:908–922.
9. Anavi S, Madar Z, Tirosh O. Nonalcoholic fatty liver disease, to struggle with the strangle: Oxygen availability in fatty livers. *Redox. Biol.* 2017;13:386–392.
10. Madiraju AK, et al. Argininosuccinate synthetase regulates hepatic AMPK linking protein catabolism and ureagenesis to hepatic lipid metabolism. *Proc. Natl. Acad. Sci. USA.* 2016;113:E3423–E3430.
11. Piatti PM, et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. *Diabetes Care.* 2001;24:875–880.
12. Ismail BS, Abdel-Reheim ES, Soliman HA, Mahmoud B. Protective effect of gallic acid against nonalcoholic fatty liver disease induced by high fat diet. *Journal of Pharmaceutical Research International,* 2021;33(44B):378-397. DOI: 10.9734/jpri/2021/v33i44B32689
13. Honda T, et al. Branched-chain amino acids alleviate hepatic steatosis and liver injury in choline-deficient high-fat diet induced NASH mice. *Metabolism.* 2017;69: 177–187.
14. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and nonalcoholic fatty liver disease. *Nutr. Metab. Cardiovasc. Dis.* 2009;19:291–302.
15. Chakravarthy MV, et al. Mechanistic insights into the multimodal effects of AXA1125 in T2D subjects with NAFLD. *Hepatology.* 70 (Supplement 1); 1264A (2019). Abstract #2134. Poster presented at Annual Meeting of the American Association for the Study of Liver Diseases. 2019. Boston, MA. Available: <https://doi.org/10.1002/hep.30941>
16. Taylor RS, et al. Outcomes of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Gastroenterology.* 2020;158:1611–1625.
17. Thomas Julie Ann, Sourya Acharya, Samarth Shukla, Joel Joy Thomas, Sree Karthik Pratapa, Vidyashree Hulkoti. Non alcoholic fatty liver disease (NAFLD) in metabolic syndrome (MetS)- A case control study. *Medical Science.* 2020; 24(103):1490–99.
18. Husain, Ayan, Anjalee Chiwhane, Vijendra Kirnake. Non-invasive assessment of liver fibrosis in alcoholic liver disease. *Clinical and Experimental Hepatology.* 2020;6(2): 125–30.

- Available:<https://doi.org/10.5114/ceh.2020.95739>.
19. Ambad RS, Nagtilak S, Bhadarge G, Kaple M. Glutathione-S-Transferase Pi and Malondialdehyde in Alcoholic Patients Attending Smhrc and Avbrh Hospital. *Journal of Pharmaceutical Research International*. 2021;33(37A):26–30.
 20. Arya, Sanjeev, Hemant Deshpande, Shantanu Belwal, Preeti Sharma, Punish Sadana, Chandrakant, Faizur Rahman, Mayank Gupta, Bhupesh Uniyal. Association between cardiac dysfunction, arrhythmias and chronic liver diseases: A narrative review. *Trends in Anaesthesia and Critical Care*. 2020;32:4–12. Available:<https://doi.org/10.1016/j.tacc.2020.03.003>.
 21. Behere, Prakash B, Amit B. Nagdive, Aniruddh P. Behere, Richa Yadav, Rouchelle Fernandes. Innovation in community psychiatry for the delivery of mental health services: The Sawangi model. *Journal of Neurosciences in Rural Practice*. 2020;11(04):593–96. Available:<https://doi.org/10.1055/s-0040-1715543>

© 2021 Kumbhare et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
<https://www.sdiarticle5.com/review-history/79781>